BA
IBRX icon

Bristlecone Advisors’s ImmunityBio IBRX Stock Holding History

Bristlecone Advisors’s Portfolio IBRX Stock Details IBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-36,000
Closed -$95K – 255
2025
Q2 		$95K Hold
36,000
– – 0.01% 239
2025
Q1 		$108K Buy
+36,000
New +$109K 0.01% 290

Other funds holding IBRX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
HCM
Heights Capital Management San Francisco, California $359M AUM 7.93% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $4.22B AUM 21.28% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Bristlecone Advisors's IBRX Position: Q3 2025 in Review

Bristlecone Advisors sold out of ImmunityBio (IBRX) in Q3 2025, closing a stake of 36,000 shares — an estimated $95K sold.

Bristlecone Advisors first reported a position in IBRX in Q1 2025 and held it in 2 quarters. The position peaked at $108K in Q1 2025. 262 funds tracked by Wall St. Rank hold IBRX as of Q3 2025.

  • Bristlecone Advisors reported no remaining ImmunityBio position as of Q3 2025 after selling out during the quarter.
  • Bristlecone Advisors sold 36,000 ImmunityBio shares in Q3 2025, an estimated $95K.
  • Bristlecone Advisors first reported a position in ImmunityBio in Q1 2025 and held it in 2 quarters.
  • Bristlecone Advisors's ImmunityBio position peaked at $108K in Q1 2025.
  • 262 funds tracked by Wall St. Rank held ImmunityBio as of Q3 2025.

Based on Bristlecone Advisors's 13F filing for Q3 2025, filed 24 Oct 2025.